Friday, February 16, 2018 10:53:16 AM
February 15, 2018 | About: CDXS +0%
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the molecular diagnostics industry by developing and commercializing high-performance enzymes for use in next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) applications. Clairmont will be responsible for all commercial activities related to the molecular diagnostics enzyme product line, including product launches and market and pricing strategies. She reports to Michael Aldridge, Codexis’ Senior VP Corporate & Strategic Development.
“We welcome Shawn to Codexis as we prepare to commercially launch our first high-performance enzymes for the molecular diagnostics industry,” said Aldridge. “Shawn brings us significant global experience in product launches and commercial account management as well as established relationships with key molecular diagnostic firms and industry opinion leaders. We look forward to calling upon her expertise in developing successful strategies as we bring new enzymes into this established market.”
Warning! GuruFocus has detected 6 Warning Signs with CDXS. Click here to check it out.
CDXS 30-Year Financial Data
The intrinsic value of CDXS
Peter Lynch Chart of CDXS
“This is an exciting time in molecular diagnostics as new technologies, such as liquid biopsy, create the need for high-performance enzymes,” said Clairmont. “Codexis is uniquely positioned to use its CodeEvolver® protein engineering platform to develop enzymes aimed at improving the sensitivity and precision of these tests in identifying biomarkers of interest. I’m delighted to join the Codexis team.”
Clairmont has 13 years of molecular diagnostics industry experience. Most recently she served as Chief Operating Officer of BRIDGenomics, a molecular diagnostics and medical device marketing consultancy providing business development and strategic marketing expertise. She previously served for eight years at the molecular diagnostics company QIAGEN in a variety of positions with increasing responsibility, most recently as Director of Sales, America, on the Global Advanced Molecular Pathology Team. Prior to QIAGEN, Clairmont was a technical marketing representative and account manager at bioArray Solutions LTD. She holds an MBA from the College of Saint Scholastica in Duluth, Minn. and a BA in biology from Saint Olaf College in Northfield, Minn.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Recent CDXS News
- Codexis Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Codexis to Report First Quarter 2024 Financial Results on May 2 • GlobeNewswire Inc. • 04/18/2024 08:05:10 PM
- Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board • GlobeNewswire Inc. • 04/11/2024 11:05:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:33 PM
- Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Biotech Rallied Strongly On Exclusive Licensing Agreement • AllPennyStocks.com • 02/27/2024 05:15:00 PM
- Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche • GlobeNewswire Inc. • 02/26/2024 09:05:42 PM
- Codexis to Participate in TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:05:47 PM
- Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board • GlobeNewswire Inc. • 02/20/2024 01:05:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:01 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:51:41 PM
- Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 • GlobeNewswire Inc. • 02/14/2024 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:19:57 PM
- Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones • GlobeNewswire Inc. • 02/13/2024 09:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:06:35 PM
- seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting • GlobeNewswire Inc. • 02/01/2024 09:05:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 07:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:40 AM
- Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108 • GlobeNewswire Inc. • 12/27/2023 01:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 01:30:30 PM
- Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase • GlobeNewswire Inc. • 12/13/2023 09:06:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM